Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

ABSTRACT:

Background

The independent French drug bulletin, La revue Prescrire (henceforth Prescrire), annually releases a list of drugs to avoid. The aim of this analysis was to review the status of the 2017 list of drugs in Canada to determine whether they had been approved for marketing, their therapeutic status and whether they have been recommended for listing on public drug plans.

Methods

This descriptive analysis reviewed a list of drugs compiled by Prescrire. The status of each drug in Canada was assessed through the Drug Product Database. Therapeutic ratings were obtained from the Patented Medicine Prices Review Board (PMPRB) and the formulary listing recommendation came from the Common Drug Review (CDR) or the pan-Canadian Oncology Drug Review (pCODR). Fo

SUBMITTER: Lexchin J 

PROVIDER: S-EPMC6182123 | biostudies-literature | 2018 Jul-Sep

REPOSITORIES: biostudies-literature